Hemorrhagic cystitis (HC) occurring after engraftment in recipients of allogeneic hematopoietic stem cell transplants (HSCT) has been associated with latent BK-virus (BKV) reactivation. In 1986, Arthur et al.
1 published a series of 53 patients showing that HC occurred four times more frequently in patients who excreted BKV than those who did not. Now, 27 years later, we know that unrelated donor transplants, mismatched-grafts and myeloablative conditioning increase the risk of BKV-related HC 2,3 and we know of the severe morbidity and negative impact on transplant outcomes it can have. However, treatment remains inadequate and relies largely on supportive care and measures to control bleeding. To date, no antiviral drug with proven efficacy against BKV replication has been licensed. This underscores the need for effective prophylaxis in our HSCT patients.
Fluoroquinolones have been shown to have in vitro activity against BKV, by inhibiting DNA gyrase and interfering with the large T-antigen helicase. 4 However, in the clinical setting, fluoroquinolones used in this way have resulted in mixed responses. 5, 6 The largest and most recent report was published by Miller et al. 6 They retrospectively analyzed consecutive HSCT patients who were given ciprofloxacin from day 0 to day 60 post transplant (N ¼ 44) and showed a significant reduction in the cumulative incidence of grades 3-4 HC compared with a historical cohort of patients (N ¼ 48) not given ciprofloxacin prophylaxis (P ¼ 0.01). At our center in Singapore, we conducted a similar analysis of a larger cohort of patients and found no benefit of ciprofloxacin prophylaxis in reducing rates of clinically significant (grade 2-4) HC; this is a report of our findings.
From September 2009, we implemented BKV monitoring and ciprofloxacin prophylaxis protocols for all patients undergoing allogeneic HSCT, and prospectively collected data on these patients to analyze the efficacy of our strategy in reducing rates of BK-related grade 2-4 HC. Monitoring with urine microscopy, urine and plasma BKV PCR levels was done at the start of conditioning and then weekly from day 14 to day 56 or until two consecutive negative BKV results after engraftment were obtained, whichever was earlier. Prophylaxis was with oral ciprofloxacin given at 500 mg bd at the start of conditioning to day 56 or until BKV load became negative. We used the intravenous preparation if patients were unable to tolerate orally and also used levofloxacin in asymptomatic patients with rising BKV titers despite ciprofloxacin. We then compared this to a similar cohort of patients transplanted during the 2 years before September 2009. Definitions for HC grading 7 and conditioning intensity were as per previously published criteria. 8 Our BKV assay was a real-time quantitative PCR targeted at VP1 protein gene of BKV with an analytical sensitivity of 333 copies/mL (at 95% CI) of plasma or urine.
In total, there were 76 patients in the BKV monitoring and ciprofloxacin group and 58 patients in the historical control group. Both groups had a median patient age of 45 years and median follow-up of 8 and 9 months, respectively. Baseline characteristics between groups were compared using Fisher's exact test and no differences were found in donor source (related vs unrelated), conditioning intensity (myeloablative vs reduced-intensity/nonmyeloablative), HLA-match and use of rabbit antithymocyte globulin. Median numbers of days on ciprofloxacin in the prophylaxis and historical groups were 46 (range 32-108) and 16.5 (0-59), respectively. The historical group received ciprofloxacin as standard anti-bacterial prophylaxis.
Our analysis showed that ciprofloxacin (or levofloxacin) failed to reduce rates of grades 2-4 HC. It developed in 16% of patients receiving prophylaxis and 15% not receiving it (P ¼ 1.0). Grade 2-4 HC was attributable to BKV in all patients. On univariate analysis, unrelated donor and HLA-mismatched transplants were significantly associated with grade 2-4 HC (P ¼ 0.006 and 0.021, respectively).
In terms of viral monitoring, viruria was detected in 75% and viraemia in 38% of patients. The presence of BK viraemia but not viruria was associated with the grades 2-4 HC (P ¼ 0.008). There was no level of BK viruria that correlated with development of HC.
Like the study by Miller et al., 6 this is a single-center experience that lacked a randomized design. However, this study, to our knowledge is the largest one to date that analyzes the efficacy of ciprofloxacin prophylaxis for BKV in allogeneic HSCT patients. Unfortunately, we found that even the strict administration of ciprofloxacin was not effective in reducing rates of clinically significant BKV-related HC. The search for effective prophylaxis should continue.
